Canada · Delayed Price · Currency is CAD InnoCan Pharma Statistics
Total Valuation
InnoCan Pharma has a market cap or net worth of CAD 10.98 million. The enterprise value is 7.96 million.
| Market Cap | 10.98M |
| Enterprise Value | 7.96M |
Important Dates
The next estimated earnings date is Tuesday, December 1, 2026.
| Earnings Date | Dec 1, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
InnoCan Pharma has 4.50 million shares outstanding. The number of shares has increased by 1.40% in one year.
| Current Share Class | 4.50M |
| Shares Outstanding | 4.50M |
| Shares Change (YoY) | +1.40% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 3.41% |
| Owned by Institutions (%) | n/a |
| Float | 3.58M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.33 |
| PB Ratio | 1.04 |
| P/TBV Ratio | 1.61 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 0.24 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.25, with a Debt / Equity ratio of 0.22.
| Current Ratio | 5.25 |
| Quick Ratio | 3.78 |
| Debt / Equity | 0.22 |
| Debt / EBITDA | n/a |
| Debt / FCF | -1.08 |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -11.81% and return on invested capital (ROIC) is -127.30%.
| Return on Equity (ROE) | -11.81% |
| Return on Assets (ROA) | -20.06% |
| Return on Invested Capital (ROIC) | -127.30% |
| Return on Capital Employed (ROCE) | -40.84% |
| Weighted Average Cost of Capital (WACC) | 2.33% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | 5 |
| Asset Turnover | 2.20 |
| Inventory Turnover | 0.94 |
Taxes
| Income Tax | -59,644 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -76.98% in the last 52 weeks. The beta is -0.26, so InnoCan Pharma's price volatility has been lower than the market average.
| Beta (5Y) | -0.26 |
| 52-Week Price Change | -76.98% |
| 50-Day Moving Average | 2.60 |
| 200-Day Moving Average | 8.39 |
| Relative Strength Index (RSI) | 51.03 |
| Average Volume (20 Days) | 3,123 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, InnoCan Pharma had revenue of CAD 33.41 million and -1.36 million in losses. Loss per share was -0.30.
| Revenue | 33.41M |
| Gross Profit | 30.22M |
| Operating Income | -4.88M |
| Pretax Income | -1.24M |
| Net Income | -1.36M |
| EBITDA | -4.83M |
| EBIT | -4.88M |
| Loss Per Share | -0.30 |
Balance Sheet
The company has 9.09 million in cash and 2.36 million in debt, with a net cash position of 6.72 million or 1.49 per share.
| Cash & Cash Equivalents | 9.09M |
| Total Debt | 2.36M |
| Net Cash | 6.72M |
| Net Cash Per Share | 1.49 |
| Equity (Book Value) | 10.53M |
| Book Value Per Share | 1.52 |
| Working Capital | 11.82M |
Cash Flow
In the last 12 months, operating cash flow was -2.17 million and capital expenditures -26,982, giving a free cash flow of -2.20 million.
| Operating Cash Flow | -2.17M |
| Capital Expenditures | -26,982 |
| Depreciation & Amortization | 50,395 |
| Net Borrowing | 905,703 |
| Free Cash Flow | -2.20M |
| FCF Per Share | -0.49 |
Margins
Gross margin is 90.46%, with operating and profit margins of -14.60% and -4.08%.
| Gross Margin | 90.46% |
| Operating Margin | -14.60% |
| Pretax Margin | -3.72% |
| Profit Margin | -4.08% |
| EBITDA Margin | -14.44% |
| EBIT Margin | -14.60% |
| FCF Margin | n/a |
Dividends & Yields
InnoCan Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -1.40% |
| Shareholder Yield | -1.40% |
| Earnings Yield | -12.41% |
| FCF Yield | -20.01% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on September 5, 2025. It was a reverse split with a ratio of 0.015384615.
| Last Split Date | Sep 5, 2025 |
| Split Type | Reverse |
| Split Ratio | 0.015384615 |
Scores
InnoCan Pharma has an Altman Z-Score of 4.16 and a Piotroski F-Score of 3.
| Altman Z-Score | 4.16 |
| Piotroski F-Score | 3 |